rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

David F. Novack

President & COO

Company insider

Files Form 4 as: President & COO, Dynavax Technologies.

Every Form 4 they filed

In numbers

Trades disclosed
200
Buys
1
Sells
27
Bought
$50K
Sold
$11.8M
Companies
1
Companies where not an officer
0
First trade
25 Mar 2013
Last trade
10 Feb 2026
Last filed
10 Feb 2026

Companies traded

Where they are an officer
Dynavax TechnologiesOfficer · Biotechnology · last 10 Feb 20261 buy · 27 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
30Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code U—63,334filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—95,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—93,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—22,620filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—37,576filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code A—67,860filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code D—67,860filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—150,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—150,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—150,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—150,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—95,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—93,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—22,620filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—37,576filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code A—56,364filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code D—56,364filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—150,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—150,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—150,000filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care1
Not placed28

Buys in green, sells in red, by the company’s sector.

Related people

Deep Track Biotechnology Master Fund, Ltd.10% owner · 10% owner at Dynavax Technologies, filing Form 4 there in the last year
Francis CanoDirector · Director at Dynavax Technologies, filing Form 4 there in the last year
Scott Dunseth MyersDirector · Director at Dynavax Technologies, filing Form 4 there in the last year
John L. SlebirSVP General Counsel · SVP General Counsel at Dynavax Technologies, filing Form 4 there in the last year
Ryan SpencerCEO and Director · CEO and Director at Dynavax Technologies, filing Form 4 there in the last year